FSDDF - FSD Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2063
+0.0063 (+3.15%)
As of 3:30PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.2000
Open0.2017
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2000 - 0.2075
52 Week Range0.0677 - 0.8750
Volume492,811
Avg. Volume413,271
Market Cap276.603M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • FSD Pharma Provides Update on Operations, Strategy and Leadership
    CNW Groupyesterday

    FSD Pharma Provides Update on Operations, Strategy and Leadership

    TORONTO , Feb. 14, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD"), a licensed producer under the Cannabis Act, today provided a corporate update on operations, strategy and leadership changes. On February 6, 2019 , the Company announced it had implemented changes in leadership and business practices to optimize operations. Accordingly, the Company announced that Dr. Raza Bokhari , Executive Co-Chairman, has been appointed interim Chief Executive Officer of FSD Pharma.

  • FSD Pharma Enters into Supply Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal
    CNW Group3 days ago

    FSD Pharma Enters into Supply Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal

    TORONTO , Feb. 12, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD"), a licensed producer under the Cannabis Act, announced today that it has entered into a supply agreement (the "Agreement") with Canntab Therapeutics Ltd. ("Canntab") and World Class Extractions Inc. ("World Class") (the "Purchasers") to purchase hemp flower from Thomas Elcome (the "Supplier"). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier's 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower.

  • FSD Pharma responds to and corrects misleading Auxly claims
    CNW Group7 days ago

    FSD Pharma responds to and corrects misleading Auxly claims

    FSD Pharma strongly denies that it caused any breaches of the Streaming Agreement relating to its management and staffing obligations or otherwise, and rejects the claim that there are material issues with the infrastructure of its cultivation facility in Cobourg, Ontario . "FSD's Board and management team are focused on taking action to deliver on a strategy that promotes growth and creates shareholder value. As disclosed on Wednesday, February 6 , FSD terminated the Definitive Agreement with Auxly.

  • Business Wire7 days ago

    FSD Pharma Responds to and Corrects Misleading Auxly Claims

    FSD Pharma Inc.(HUGE.CN) (FSDDF) (0K9.F) a licensed producer under the Cannabis Act, responded today to a press release by its former partner, Auxly Cannabis Group Inc. (“Auxly”) to correct misleading claims. FSD Pharma strongly denies that it caused any breaches of the Streaming Agreement relating to its management and staffing obligations or otherwise, and rejects the claim that there are material issues with the infrastructure of its cultivation facility in Cobourg, Ontario. “FSD’s Board and management team are focused on taking action to deliver on a strategy that promotes growth and creates shareholder value.

  • Business Wire9 days ago

    FSD Pharma Signs Collaboration and Profit-Sharing Agreement with Pharmastrip for Production and Delivery of Organic Medical Cannabis Infused in Oral Thin Film Strips

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company), a licensed producer under the Cannabis Act, announced today that it has completed a strategic investment of $1.5 million in Pharmastrip Corp. and signed a definitive collaboration and profit sharing agreement with the company, effective January 23, 2019. Under the terms of the agreement, FSD will install Pharmastrip proprietary equipment at its facility in Cobourg, Ontario.

  • FSD Pharma Announces Strategic Business Developments
    CNW Group9 days ago

    FSD Pharma Announces Strategic Business Developments

    TORONTO , Feb. 6, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), announced that its Board of Directors has concluded a strategic assessment of the Company and has implemented changes in leadership and business practices to optimize operations. Accordingly, the Company announced today that Dr. Raza Bokhari , Executive Co-Chairman, has been appointed interim Chief Executive Officer of FSD Pharma, effective immediately.

  • Newsfile9 days ago

    InvestmentPitch Media Video Discusses Licensed Cannabis Producer FSD Pharma's LOI with Solarvest BioEnergy to Develop and Test Production of Pharma-Grade Cannabinoids from Algae - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - February 6, 2019) -  FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), a licensed cannabis producer, has signed a non-binding letter of intent with Solarvest BioEnergy Inc. to develop and test the production of pharma-grade cannabinoids from algae.Solarvest BioEnergy Inc. (TSXV:SVS), an algae technology company, has developed a platform capable of producing health products such as "Organic Omega 3 DHA" fruit gummies and food boosting powders, and has ...

  • GlobeNewswire9 days ago

    FSD Pharma Looks to Grow Cannabinoids in Algae -- CFN Media

    SEATTLE, Feb. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article looking at what makes algae a unique platform for cannabinoid production, as well as how the new agreement with Solarvest fits into FSD Pharma’s plans to become a leading cannabis producer. FSD Pharma Inc. (CSE:HUGE) (FSDDF) (FRK:0K9) recently signed a letter of intent with Solarvest BioEnergy Inc. to apply Solarvest’s algae platform to develop pharmaceutical grade cannabinoids. The move could dramatically disrupt current cannabinoid procurement methods by reducing the time, space, and costs associated with cannabis cultivation, particularly for medical cannabis subject to GMP certification standards.

  • CNW Group11 days ago

    FSD Pharma Announces Signing of LOI with Solarvest to Develop and Test Pharma-Grade Cannabinoids out of Algae

    TORONTO , Feb. 5, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) ("FSD Pharma") and Solarvest BioEnergy Inc. (SVS.V) ("Solarvest") (collectively, the "Parties"), a technology company which has developed an algal-based flexible production platform capable of producing health products, are pleased to announce that they have signed a non-binding letter of intent ("LOI"). The parties intend to enter into a definitive agreement (the "Collaborative Research Agreement"), under which Solarvest would conduct research using its algal expression technology to develop pharma-grade cannabinoids (the "Project Cannabinoids"), the Parties would make mutual investments into one another, and Solarvest would grant FSD Pharma an exclusive license over a subset of the Project Cannabinoids and certain royalty rights over all of the other Project Cannabinoids.

  • FSD Pharma Congratulates High Tide Inc. for Signing LOI with Winner of Ontario Retail License Lottery to Operate Cannabis Retail Store
    CNW Group11 days ago

    FSD Pharma Congratulates High Tide Inc. for Signing LOI with Winner of Ontario Retail License Lottery to Operate Cannabis Retail Store

    TORONTO , Feb. 4, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (FRA:OK9) ("FSD Pharma" or the "Company") would like to congratulate High Tide Inc. ("High Tide") for entering into a letter of intent with a winner of one of the 25 opportunities to apply for a license to operate a cannabis retail store (the "Winner") as a result of the Alcohol and Gaming Commission of Ontario's Expression of Interest Application Lottery conducted on January 11, 2019 . Under the terms of the LOI, High Tide will acquire a minority interest in the Winner and will assist the Winner with establishing and operating a cannabis retail store in Ontario . "The announcement today by our partners High Tide is exciting news.

  • GlobeNewswire18 days ago

    How Cannabinoids Could Replace Opioids -- CFN Media

    SEATTLE, Jan. 28, 2019 -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry,.

  • GlobeNewswire29 days ago

    FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media

    SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE:HUGE) (FSDDF) (0K9.F) & Canntab Therapeutics Ltd’s. (CSE:PILL) (TBF1.F) performance in 2018. The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond.

  • Business Wirelast month

    FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE

    FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange ("CSE") today under the stock symbol "LOVE". FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. Anthony Durkacz, Co-Chairman of the Board and Co-Founder of FSD, said, "I want to congratulate Zohar Krivorot and his team at Cannara for achieving this significant milestone and for their ongoing efforts to build out the largest indoor cannabis grow facility in Quebec.

  • CNW Grouplast month

    FSD Pharma Announces Holdings in Cannara Biotech Inc.

    TORONTO , Jan. 11, 2019 /CNW/ - FSD Pharma ("FSD") announced today that, in connection with the business combination (the "Business Combination") completed on December 31, 2018 among Cannara Biotech Inc. (formerly, Dunbar Capital Corp.) (the "Issuer"), Cannara Biotech Inc. and 11038427 Canada Inc., FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.

  • Business Wirelast month

    FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot

    FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Cannabis Act, has completed the harvest of its second lot of cannabis and successfully passed all analytical testing, thereby positioning the Company to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the Cannabis Act and Regulations.

  • Newsfile2 months ago

    InvestmentPitch Media Video Discusses Licensed Cannabis Producer FSD Pharma's Investment in Cannabis Retailer, Huge Shops, Gaining Strategic Access to Chairman's Brands' Coffee Time Retail Network - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - December 24, 2018) -  FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), a licensed cannabis producer, has invested $1.3 million to acquire approximately 9.9% of Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with privately held Chairman's Brands, based in Toronto, and one of the largest and fastest growing franchising companies in Canada, with a global presence in Europe and the Middle East.InvestmentPitch.com has ...

  • Business Wire2 months ago

    FSD Pharma Responds to Therapix Termination of Binding LOI

    On October 22, FSD Pharma announced the signing of the binding LOI to acquire Therapix Biosciences as part of the company’s strategic objective to develop pharmaceutical assets in the cannabinoid research space.

  • GlobeNewswire2 months ago

    Canntab & FSD Pharma Make Cannabis More Palatable for Doctors -- CFN Media

    SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F). The company is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.